Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Approaches to mitigate the risk of serious adverse reactions in covalent drug design
Thomas A. Baillie
Expert Opinion on Drug Discovery (2020) Vol. 16, Iss. 3, pp. 275-287
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials
Beatrice Noce, Elisabetta Di Bello, Rossella Fioravanti, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 75
Boronic acid with high oxidative stability and utility in biological contexts
Brian J. Graham, Ian W. Windsor, Brian Gold, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 10
Open Access | Times Cited: 76
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Robert Roskoski
Pharmacological Research (2021) Vol. 165, pp. 105422-105422
Closed Access | Times Cited: 74
Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development
Fangjiao Huang, Xiaoli Han, Xiaohui Xiao, et al.
Molecules (2022) Vol. 27, Iss. 22, pp. 7728-7728
Open Access | Times Cited: 60
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Hossam Nada, Yongseok Choi, Sung-Do Kim, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices
Abdul-Quddus Kehinde Oyedele, Abdeen Tunde Ogunlana, Ibrahim Damilare Boyenle, et al.
Molecular Diversity (2022) Vol. 27, Iss. 4, pp. 1879-1903
Open Access | Times Cited: 27
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2
Wenying Yu, Yucheng Zhao, Hui Ye, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16252-16267
Closed Access | Times Cited: 25
Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer
Thirumagal Thiyagarajan, Suriyan Ponnusamy, Dong‐Jin Hwang, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 120, Iss. 1
Open Access | Times Cited: 24
Covalent drug – An emerging framework for targeted drug development
Ritesh P. Bhole, Govinda O. Joshi, Harshad S. Kapare, et al.
Results in Chemistry (2024) Vol. 8, pp. 101615-101615
Open Access | Times Cited: 5
Genetically encoding latent bioreactive amino acids and the development of covalent protein drugs
Nanxi Wang, Lei Wang
Current Opinion in Chemical Biology (2021) Vol. 66, pp. 102106-102106
Closed Access | Times Cited: 28
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
Kirsten McAulay, Alan Bilsland, Marta Bon
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1366-1366
Open Access | Times Cited: 22
UBE2N: Hope on the Cancer Front, How to Inhibit This Promising Target Prospect?
Florian Schwalen, Côme Ghadi, Léonie Ibazizene, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Covalent drugs
M Kucerová
Česká a slovenská farmacie (2025) Vol. 74, Iss. 1, pp. E11-E16
Closed Access
Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology
Natalia Sacilotto, Paola Dessanti, Michele MP Lufino, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 6, pp. 1818-1834
Open Access | Times Cited: 27
Protein Haptenation and Its Role in Allergy
Maja Aleksić, Xiaoli Meng
Chemical Research in Toxicology (2024) Vol. 37, Iss. 6, pp. 850-872
Open Access | Times Cited: 3
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53
Theresa Klett, Martin Schwer, Larissa N. Ernst, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2653-2679
Open Access | Times Cited: 3
A Medicinal Chemistry Perspective on FDA-Approved Small Molecule Drugs with a Covalent Mechanism of Action
Samuel E. Dalton, Ornella Di Pietro, Elisabeth T. Hennessy
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods
Yiming Wen, Peijia Xu, Yijie Chen, et al.
Molecular Diversity (2025)
Closed Access
Recent highlights in covalent inhibitor design
Kristen A. Marino, Robert Nicewonger, Hailong Zhang, et al.
Elsevier eBooks (2025)
Closed Access
Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines
Daiki Yamane, Ryo Tetsukawa, Naoki Zenmyo, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 9130-9146
Closed Access | Times Cited: 9
Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK
Michael Förster, Xiaojun Julia Liang, Martin Schröder, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 9269-9269
Open Access | Times Cited: 22
Overview of Adductomics in Toxicology
Oksana Lockridge
Current Protocols (2023) Vol. 3, Iss. 2
Open Access | Times Cited: 7
Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review
Muhammad Salman Hameed, Hongxuan Cao, Li Guo, et al.
European Journal of Medicinal Chemistry Reports (2024), pp. 100217-100217
Open Access | Times Cited: 2
Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat
Jonathan Werner, Rhian Davies, Jan L. Wahlstrom, et al.
Toxicology and Applied Pharmacology (2021) Vol. 423, pp. 115578-115578
Closed Access | Times Cited: 13
Trends in covalent drug discovery: a 2020-23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in fda-approved drugs
Jan Felix Scholtes, Cristóbal Alhambra, Philip A. Carpino
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 843-861
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top